LivingGLP1
Study S000404

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration
NCT01722266
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
TRIPLE
Status
COMPLETED
Enrollment
72
Start
2012-11-01
Primary completion
2014-04-01
Lead sponsor
University at Buffalo
Conditions
Type 1 Diabetes
Interventions
DRUG:Liraglutide; DRUG:Placebo
Results posted
TRUE

Registered primary outcomes

  • Change in Mean Weekly Glucose Concentrations [12 Weeks]

Linked records (9)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0026291Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Kuhadiya ND, Diabetes care
2016Randomized trialPMID 27208343DOIcites ClinicalTrials.gov:NCT01722266; registry reference DERIVED:27208343
R0027017Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Kuhadiya ND, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2013Nonrandomized studyPMID 23807520DOIregistry reference BACKGROUND:23807520
R0016426Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
Varanasi A, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2012Nonrandomized studyPMID 21856595DOIregistry reference BACKGROUND:21856595
R0026872Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.
Varanasi A, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2011Nonrandomized studyPMID 20841306DOIregistry reference BACKGROUND:20841306
R0027423Liraglutide as additional treatment for type 1 diabetes.
Varanasi A, European journal of endocrinology
2011OtherPMID 21646283DOIregistry reference BACKGROUND:21646283
R0024803Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
Okerson T, American journal of hypertension
2010Randomized trialPMID 20019672DOIregistry reference BACKGROUND:20019672
R0021040A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E, Clinical therapeutics
2009Other trialPMID 20109994DOIregistry reference BACKGROUND:20109994
R0027271Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Rother KI, Diabetes care
2009Randomized trialPMID 19808924DOIregistry reference BACKGROUND:19808924
R0026490Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB, Clinical therapeutics
2007Randomized trialPMID 17379054DOIregistry reference BACKGROUND:17379054